Literature DB >> 10487716

A gene for congenital generalized lipodystrophy maps to human chromosome 9q34.

A Garg1, R Wilson, R Barnes, E Arioglu, Z Zaidi, F Gurakan, N Kocak, S O'Rahilly, S I Taylor, S B Patel, A M Bowcock.   

Abstract

Congenital generalized lipodystrophy (CGL, Berardinelli-Seip Syndrome, OMIM # 269700) is a rare autosomal recessive disorder characterized by near complete absence of adipose tissue from birth. Affected individuals have marked insulin resistance, hypertriglyceridemia and acanthosis nigricans, and develop diabetes mellitus during teenage years. The genetic defect for CGL is unknown. A semi-automated genome-wide scan with a set of highly polymorphic short tandem repeats (STR) was carried out in 17 well-characterized pedigrees and identified a locus for CGL to chromosome 9q34. The maximum two-point lod score obtained was 3.6 at D9S1818 (theta(max) = 0.05). There was evidence for genetic heterogeneity (alpha = 0.73) and 2 of the pedigrees were unlinked. Multipoint linkage analysis excluding the 2 unlinked families yielded a peak lod score of 5.4 between loci D9S1818 and D9S1826. The CGL1 critical region harbors a plausible candidate gene encoding the retinoid X receptor alpha (RXRA) that plays a central role in adipocyte differentiation. Identification of the CGL gene(s) will contribute to our understanding of the adipocyte differentiation and elucidation of the mechanisms of insulin resistance in disorders of adipose tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487716     DOI: 10.1210/jcem.84.9.6103

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice.

Authors:  O Gavrilova; B Marcus-Samuels; D Graham; J K Kim; G I Shulman; A L Castle; C Vinson; M Eckhaus; M L Reitman
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 2.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

3.  Berardinelli-Seip lipodystrophy.

Authors:  Yuko Kobashi; Amy Schoenbaum; Robert P Hasserjian; Daniel I Rosenthal
Journal:  Skeletal Radiol       Date:  2007-06-07       Impact factor: 2.199

Review 4.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

Review 5.  Seipin: from human disease to molecular mechanism.

Authors:  Bethany R Cartwright; Joel M Goodman
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

6.  Berardinelli Seip Syndrome.

Authors:  Col An Prasad
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  In vivo formation of bone and haematopoietic territories by transplanted human bone marrow stromal cells generated in medium with and without osteogenic supplements.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Pamela Gehron Robey
Journal:  J Tissue Eng Regen Med       Date:  2011-11-03       Impact factor: 3.963

Review 8.  Congenital lipodystrophies and dyslipidemias.

Authors:  Xavier Prieur; Cedric Le May; Jocelyne Magré; Bertrand Cariou
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

9.  Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Paolo Bianco; Pamela G Robey
Journal:  Stem Cell Res       Date:  2008-08-12       Impact factor: 2.020

10.  The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation.

Authors:  Weiqin Chen; Vijay K Yechoor; Benny Hung-Junn Chang; Ming V Li; Keith L March; Lawrence Chan
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.